CDMO News and Research

RSS

Wavelength Pharmaceuticals expands supplies of key drug ingredients for critically ill COVID-19 patients

Wavelength Pharmaceuticals, a leading supplier of active pharmaceutical ingredients, today reported that it has greatly expanded production of APIs for certain pharmaceutical products needed to manage respiratory critical care patients.

20 Apr 2020

Cobra Biologics and Karolinska Institutet join forces to develop DNA vaccine against COVID-19

Cobra Biologics, an international CDMO for biologics and pharmaceuticals, and the Karolinska Institutet, one of the world’s leading medical universities, today announced they have been awarded €3 million emergency funding by Horizon 2020 for research and development, and phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium to support global efforts tackling the pandemic.

31 Mar 2020

New partnership enables launch of POCare cell therapy platform within HYGEIA Group’s hospital network

Orgenesis Inc., a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services through its subsidiary Masthercell Global, Inc., as well as localized point-of-care development and processing centers for therapeutic treatments, today announces a strategic partnership agreement between the HYGEIA Group and the Theracell–Orgenesis joint venture.

9 Dec 2019

Yposkesi chairman to speak on ‘Manufacturing and the CDMO Perspective’ at Cell and Gene Meeting

Yposkesi, a leading CDMO for gene therapy viral vector manufacturing, today announces that its chairman Frederic Revah Ph.D. will participate as a panelist on the topic of ‘Manufacturing and the CDMO Perspective’.

23 Apr 2019

Cobra Biologics announces appointment of Dr Darrell Sleep as Director of Innovation

Cobra Biologics, an international CDMO for biologics and pharmaceuticals, today announced the appointment of Dr Darrell Sleep as Director of Innovation.

From Charles River 16 Jan 2019

Cobra Biologics to investigate continuous manufacturing of AAV for gene therapies

Cobra Biologics, an international contract development and manufacturing organization with a focus on advanced therapy medicinal products has won a £1.5m shared grant from Innovate UK, the United Kingdom’s innovation agency.

28 Nov 2018

FDA approves manufacturing of Insmed's ARIKAYCE at Therapure Biopharma's Mississauga facility

Therapure Biomanufacturing, an integrated contract development and manufacturing organization and a division of Therapure Biopharma Inc., today announced approval for the manufacturing of Insmed Incorporated's ARIKAYCE® at its Mississauga facility by the U.S. Food and Drug Administration.

3 Oct 2018

Celltrion and Emory University sign 'Incubation' agreement to develop new drug candidates for atherosclerosis

Celltrion, Inc. signed an 'Incubation' agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis.

20 Sep 2018

Ology Bioservices wins $8.4 million worth agreement to manufacture anti-Ebola monoclonal antibody

Ology Bioservices, Inc., a biologics contract development and manufacturing organization, announced today that it was awarded an Other Transaction Agreement to support the Joint Project Manager Medical Countermeasure Systems, a component of the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense for advanced biologics manufacturing services—specifically, to manufacture an anti-Ebola monoclonal antibody.

17 Aug 2018

Minakem's new high-class production facility extends capacity to develop and manufacture HPAPI compounds

Minakem, the CDMO division of Minafin, specialized in custom development and manufacturing of building blocks, GMP intermediates and Active Pharmaceutical Ingredients, today announces it is in the final qualification run to open a new closed-controlled environment high containment production facility in August.

22 Jun 2018

Vetter's new campaign aims to examine applicability of digital trends to injection systems

How can digital trends be used purposefully in regards to the application of injection systems? That is the key question being addressed by Vetter’s Open Innovation Challenge.

13 Jun 2018

Abzena selects Sartorius Stedim Biotech as preferred equipment supplier in the U.S

Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.

From Sartorius 9 Feb 2018

CPhI Pre-Connect Congress to provide insights on major developments in pharmaceutical industry

CPhI Worldwide, organized by UBM EMEA, announces the upcoming trends in the 8th edition of the CPhI Pre-Connect Congress, taking place on October 3rd.

26 Aug 2016

Xcelience announces grand opening of new headquarters in Tampa

Xcelience is proud to announce the grand opening of its new 71,000 square foot headquarters located at 4910 Savarese Circle in Tampa. The building houses preformulation and formulation development labs and suites, as well as analytical and stability services. The official ribbon cutting ceremony was attended by Florida Governor Rick Scott, Tampa Mayor Bob Buckhorn and other elected and non-elected officials.

31 Oct 2015

Lupin signs strategic asset purchase agreement with Temmler

Pharma Major Lupin Limited today announced that it has entered into a strategic asset purchase agreement with TEMMLER PHARMA GMBH & CO. KG, a part of the Aenova Group, one of the world's largest pharmaceutical contract manufacturers, to acquire Temmler's specialty product portfolio subject to certain closing conditions.

25 Jul 2015

Takara Bio Europe launches Cellartis DEF-CS Xeno-Free Culture Medium for iPS cell culture

Takara Bio Europe AB, formerly Cellartis AB, a wholly-owned subsidiary of Takara Bio Inc., announced today that it is launching an advanced cell culture medium for iPS cell culture. This chemically-defined culture medium is pre-clinical grade, free from human- and animal-derived components, and designed for efficient expansion of undifferentiated human iPS cells.

3 Jun 2015

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Goodwin Biotechnology, Inc., a biological Contract Development and Manufacturing Organization that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing Mammalian Cell Culture expression systems and Bioconjugation technologies, was selected by Panacea Pharmaceuticals, Inc. to complete a novel Fill / Finish project, as well as Quality Control release and stability testing for a therapeutic, nanoparticle cancer vaccine based on the Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH) tumor-specific protein to support Phase I clinical trials in patients with various solid tumor cancers.

11 May 2015